What's Happening?
AstraZeneca's cancer immunotherapy drug, Imfinzi, has received approval in the European Union for use in early-stage gastric cancer treatment. This approval follows its earlier acceptance in the United States. Imfinzi, a PD-L1 inhibitor, is to be used
in combination with standard chemotherapy in both pre-surgery (neoadjuvant) and post-surgery (adjuvant) settings, followed by Imfinzi monotherapy as maintenance. The approval is based on the MATTERHORN trial, which demonstrated a 29% improvement in event-free survival and a 22% increase in overall survival compared to chemotherapy alone. This development positions Imfinzi favorably against MSD's Keytruda, which did not show similar benefits in a comparable trial.
Why It's Important?
The approval of Imfinzi for early-stage gastric cancer is significant as it offers a new treatment option that could improve survival rates for patients. This development may influence the use of other PD-(L)1 inhibitors like Keytruda, Opdivo, and Tevimbra, which are currently used in advanced stages of the disease. The success of Imfinzi in the MATTERHORN trial could lead to its adoption as a standard treatment, potentially impacting the market dynamics for gastric cancer therapies. AstraZeneca's strategic positioning with Imfinzi could also drive its sales, which have already seen a significant increase.
What's Next?
AstraZeneca is seeking further approvals for Imfinzi in other cancer types, including bladder, liver, and lung cancers, based on ongoing trials. The company aims to expand its market share in the oncology sector by leveraging the success of Imfinzi in various treatment settings. The impact of this approval on the use of other immunotherapies in gastric cancer will be closely monitored by oncologists and could lead to changes in treatment protocols.
